Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency (IGHD)
26 février 2013 mis à jour par: Pfizer
Prospective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study)
The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass.
Aperçu de l'étude
Statut
Résilié
Les conditions
Intervention / Traitement
Description détaillée
The study was terminated on 15-Dec-2008 due to poor recruitment.
Although 9 Patients were enrolled, no patient was randomized nor treated with somatropin.
No safety reasons contributed to the termination.
Type d'étude
Interventionnel
Inscription (Réel)
9
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Bad Aibling, Allemagne, 83043
- Pfizer Investigational Site
-
Muenchen, Allemagne, 80804
- Pfizer Investigational Site
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 65 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Males and females between 18 and 65 years of age
- Isolated growth hormone deficiency
Exclusion Criteria:
- Isolated growth hormone deficiency by childhood onset
- Diabetes mellitus type 1 or 2
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase.
To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels.
Central lab will randomize placebo patients to dose change or maintenance of dose.
This will ensure continued blinding of the study to patients and personnel.
|
|
Comparateur actif: Verum
|
Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg.
for the first 4 weeks half of the dose will be given.
After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range.
In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks).
At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI)
Délai: Baseline, 52 weeks
|
Fat measurements carried out with the subjects lying in a supine position in a MRI scanner.
Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.
|
Baseline, 52 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Visceral Fat Mass in Subgroups
Délai: Baseline, 52 weeks, 78 weeks
|
Change in visceral fat mass in subgroups.
Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors.
Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).
|
Baseline, 52 weeks, 78 weeks
|
|
Change From Baseline in Anthropometric Parameters (Height)
Délai: Baseline, 52 weeks, 78 weeks
|
Baseline, 52 weeks, 78 weeks
|
|
|
Change From Baseline in Anthropometric Parameters (Weight)
Délai: Baseline, 52 weeks, 78 weeks
|
Baseline, 52 weeks, 78 weeks
|
|
|
Change From Baseline in Anthropometric Parameters (Waist Circumference)
Délai: Baseline, 52 weeks, 78 weeks
|
Baseline, 52 weeks, 78 weeks
|
|
|
Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT])
Délai: Baseline, Week 52, Week 78
|
Alertness: software-based neuropsychological assessment for response time and errors.
Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C).
Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Blood Pressure
Délai: Baseline, Week 52, Week 78
|
Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg.
The same arm (preferably the dominant arm) was used throughout the trial.
The subject was seated for 5 minutes before the blood pressure was obtained.
Use of an automated device could have been used for measuring blood pressure.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Heart Rate
Délai: Baseline, Week 52, Week 78
|
The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.
|
Baseline, Week 52, Week 78
|
|
Change in Executive Function and Memory in Subgroups
Délai: Baseline, Week 52, Week 78
|
Change in executive function and memory in subgroups.
Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors.
Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).
Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Safety Laboratory Assessments
Délai: Baseline, Week 52, Week 78
|
Prespecified safety laboratory assessments evaluated for change or no change from baseline.
Possible responses were Yes/No.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Homeostasis Model Assessment (HOMA)-Index
Délai: Baseline, Week 52, Week 78
|
HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)
Délai: Baseline, Week 52, Week 78
|
Participant self administered questionnaire consisting of 25 items that evoke yes or no answers.
A score of 1 is given to each item affirmed and these are summed to give the total score.
The maximum score is 25, which represents a poor quality of life.
The minimum score is 0, which represents a good quality of life.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Short Form (36) Health Survey (SF36)
Délai: Baseline, Week 52, Week 78
|
Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT).
Scale range 0 to 100, higher scores indicate a better health-related quality of life.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D)
Délai: Baseline, Week 52, Week 78
|
Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument.
The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression.
Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem).
The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.
|
Baseline, Week 52, Week 78
|
|
Change From Baseline in Cardiovascular Risk Factors
Délai: Baseline, Week 52, Week 78
|
Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)
|
Baseline, Week 52, Week 78
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 mai 2008
Achèvement primaire (Réel)
1 octobre 2008
Achèvement de l'étude (Réel)
1 octobre 2008
Dates d'inscription aux études
Première soumission
28 février 2008
Première soumission répondant aux critères de contrôle qualité
28 février 2008
Première publication (Estimation)
7 mars 2008
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
4 mars 2013
Dernière mise à jour soumise répondant aux critères de contrôle qualité
26 février 2013
Dernière vérification
1 février 2013
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies musculo-squelettiques
- Maladies hypothalamiques
- Maladies osseuses
- Maladies osseuses, endocriniennes
- Maladies de l'hypophyse
- Nanisme
- Maladies osseuses, développement
- Hypopituitarisme
- Nanisme, hypophyse
- Maladies du système endocrinien
Autres numéros d'identification d'étude
- A6281282
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .